Trevi Therapeutics, Inc. Common Stock

TRVINASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
13.33 USD
↘ 0.60 (4.31%)AT CLOSE (11:59 AM EDT)
13.34
↗ 0.01 (0.08%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
13.34
↗ 0.01 (0.08%)
🔴Market: CLOSED
Open?$13.86
High?$13.93
Low?$13.31
Prev. Close?$13.93
Volume?729.3K
Avg. Volume?1.3M
VWAP?$13.56
Rel. Volume?0.56x
Bid / Ask
Bid?$12.50 × 100
Ask?$13.33 × 1.3K
Spread?$0.83
Midpoint?$12.92
Valuation & Ratios
Market Cap?1.9B
Shares Out?142.0M
Float?118.3M
Float %?83.3%
P/E Ratio?N/A
P/B Ratio?11.00
EPS?-$0.32
Dividend?0.00%
Ex-Dividend?N/A

Shares of Trevi Therapeutics, Inc. Common Stock (TRVI) are trading at $13.33. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, TRVI is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Themes
Biotech - Drug Development›Clinical-Stage Platforms
Employees
34
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.trevitherapeutics.com
Listed
2019-05-03
Address
195 CHURCH STREET
NEW HAVEN, CT 06510
Phone: 203-304-2499
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?149.32Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.24%High
Short Interest?13.3M
Days to Cover?8.7
Free Float118.3M
Avg Daily Volume1.5M
Settlement Date2026-05-15
Financial Health
Current Ratio?24.75Strong
Quick Ratio?24.75Strong
Cash Ratio?2.73Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
18
11.00HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-35.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-26.5%WEAK▾
ROA?
S&P
3
-25.4%WEAK▾
Cash Flow & Enterprise
FCF?$-45415000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day
MarketsMoversWatchlist